FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171973389> ?p ?o ?g. }

• W2171973389 endingPage "2405" @default.
• W2171973389 startingPage "2405" @default.
• W2171973389 abstract "<h3>Background</h3> Optimal public health strategies for managing influenza vaccine shortages are not yet defined. Our objective was to determine the effects of age, sex, and dose on the immunogenicity of intramuscular trivalent inactivated vaccine (TIV). <h3>Methods</h3> Healthy adults aged 18 to 64 years, stratified by age (18-49 and 50-64 years) and sex, were randomized to receive full- or half-dose TIV. Hemagglutination inhibition titers against vaccine antigens were measured before and 21 days after immunization. A primary outcome of noninferiority was defined as a difference of less than 20% in the upper 95% confidence interval (CI) of the proportion of subjects with strain-specific hemagglutination inhibition antibody titers of 1:40 or higher after vaccination. Secondary outcomes included geometric mean titers, after vaccination side effects, and occurrences of influenza-like illnesses. <h3>Results</h3> Among previously immunized subjects (N = 1114) receiving half- vs full-dose TIV (age, 18-49 years, n = 284 [half] and n = 274 [full]; and age 50-64 years, n = 276 [half] and n = 280 [full]), CIs for proportions of subjects with hemagglutination inhibition antibody titers of 1:40 or higher excluded substantial reduction for all antigens in the 18- to 49-year age group and for B/Shanghai/361/2002 (B) and A/Fujian/411/2002 (A/H3N2) in the 50- to 64-year age group. Geometric mean titer in the female 18- to 49-year age group exceeded male responses for all strains: responses to half-dose TIV that were comparable with male full-dose responses for A/New Caledonia/20/99 (A/H1N1) antigen, 25.4 (95% CI, 20.9-30.9) vs 25.6 (95% CI, 21.3-30.9); A/H3N2 antigen, 60.8 (95% CI, 50.8-72.7) vs 44.1 (95% CI, 37.6-51.8); and B antigen, 64.4 (95% CI, 53.9-76.9) vs 60.7 (95% CI, 51.4-71.7) (findings were similar for the 50- to 64-year age group). Some injection site and systemic reactions (myalgias and/or arthralgias [<i>P</i> < .05], headache [<i>P</i> < .001], and impact of fatigue [<i>P</i> < .05]) were significantly lower in men. The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose groups regardless of age. <h3>Conclusions</h3> Antibody responses to intramuscular half-dose TIV in healthy, previously immunized adults were not substantially inferior to the full-dose vaccine, particularly for ages 18 to 49 years. Significantly higher geometric mean titer responses in women were identified for all ages, regardless of dose or influenza strain. Half-dose vaccination may be an effective strategy for healthy adults younger than 50 years in the setting of an influenza vaccine shortage. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00283283" @default.
• W2171973389 created "2016-06-24" @default.
• W2171973389 creator A5009596557 @default.
• W2171973389 creator A5033184432 @default.
• W2171973389 creator A5034353648 @default.
• W2171973389 creator A5036388273 @default.
• W2171973389 creator A5042340561 @default.
• W2171973389 creator A5076837032 @default.
• W2171973389 creator A5081646689 @default.
• W2171973389 creator A5082827429 @default.
• W2171973389 creator A5083732628 @default.
• W2171973389 creator A5088325370 @default.
• W2171973389 creator A5089157167 @default.
• W2171973389 date "2008-12-08" @default.
• W2171973389 modified "2023-10-16" @default.
• W2171973389 title "Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)" @default.
• W2171973389 cites W1487018400 @default.
• W2171973389 cites W1498254778 @default.
• W2171973389 cites W1513779155 @default.
• W2171973389 cites W1520538169 @default.
• W2171973389 cites W1618733816 @default.
• W2171973389 cites W1886211768 @default.
• W2171973389 cites W1966893415 @default.
• W2171973389 cites W1971462013 @default.
• W2171973389 cites W1981637354 @default.
• W2171973389 cites W1986209227 @default.
• W2171973389 cites W1995731966 @default.
• W2171973389 cites W2010802368 @default.
• W2171973389 cites W2016143593 @default.
• W2171973389 cites W2021722652 @default.
• W2171973389 cites W2029401897 @default.
• W2171973389 cites W2029758745 @default.
• W2171973389 cites W2039190197 @default.
• W2171973389 cites W2056314055 @default.
• W2171973389 cites W2062190875 @default.
• W2171973389 cites W2064391381 @default.
• W2171973389 cites W2067458777 @default.
• W2171973389 cites W2090889765 @default.
• W2171973389 cites W2095044543 @default.
• W2171973389 cites W2098900658 @default.
• W2171973389 cites W2105974132 @default.
• W2171973389 cites W2111973875 @default.
• W2171973389 cites W2113665122 @default.
• W2171973389 cites W2117249292 @default.
• W2171973389 cites W2120914209 @default.
• W2171973389 cites W2131828349 @default.
• W2171973389 cites W2139841187 @default.
• W2171973389 cites W2146483267 @default.
• W2171973389 cites W2152368843 @default.
• W2171973389 cites W2159880992 @default.
• W2171973389 cites W2163369593 @default.
• W2171973389 cites W2170456252 @default.
• W2171973389 cites W2171961487 @default.
• W2171973389 cites W2187853964 @default.
• W2171973389 cites W2315861356 @default.
• W2171973389 cites W2319963574 @default.
• W2171973389 cites W2321609861 @default.
• W2171973389 cites W2339696769 @default.
• W2171973389 cites W2339913251 @default.
• W2171973389 cites W3020150929 @default.
• W2171973389 cites W1990024681 @default.
• W2171973389 doi "https://doi.org/10.1001/archinternmed.2008.513" @default.
• W2171973389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19064822" @default.
• W2171973389 hasPublicationYear "2008" @default.
• W2171973389 type Work @default.
• W2171973389 sameAs 2171973389 @default.
• W2171973389 citedByCount "246" @default.
• W2171973389 countsByYear W21719733892012 @default.
• W2171973389 countsByYear W21719733892013 @default.
• W2171973389 countsByYear W21719733892014 @default.
• W2171973389 countsByYear W21719733892015 @default.
• W2171973389 countsByYear W21719733892016 @default.
• W2171973389 countsByYear W21719733892017 @default.
• W2171973389 countsByYear W21719733892018 @default.
• W2171973389 countsByYear W21719733892019 @default.
• W2171973389 countsByYear W21719733892020 @default.
• W2171973389 countsByYear W21719733892021 @default.
• W2171973389 countsByYear W21719733892022 @default.
• W2171973389 countsByYear W21719733892023 @default.
• W2171973389 crossrefType "journal-article" @default.
• W2171973389 hasAuthorship W2171973389A5009596557 @default.
• W2171973389 hasAuthorship W2171973389A5033184432 @default.
• W2171973389 hasAuthorship W2171973389A5034353648 @default.
• W2171973389 hasAuthorship W2171973389A5036388273 @default.
• W2171973389 hasAuthorship W2171973389A5042340561 @default.
• W2171973389 hasAuthorship W2171973389A5076837032 @default.
• W2171973389 hasAuthorship W2171973389A5081646689 @default.
• W2171973389 hasAuthorship W2171973389A5082827429 @default.
• W2171973389 hasAuthorship W2171973389A5083732628 @default.
• W2171973389 hasAuthorship W2171973389A5088325370 @default.
• W2171973389 hasAuthorship W2171973389A5089157167 @default.
• W2171973389 hasBestOaLocation W21719733891 @default.
• W2171973389 hasConcept C126322002 @default.
• W2171973389 hasConcept C159654299 @default.
• W2171973389 hasConcept C182072434 @default.
• W2171973389 hasConcept C187212893 @default.
• W2171973389 hasConcept C203014093 @default.
• W2171973389 hasConcept C22070199 @default.

• next